News on Inflammation from BioPortfolio.com http://www.BioPortfolio.com Consolidated Inflammation news from BioPortfolio.com Tue, 09 Feb 2010 22:19:29 GMT en Inflammation Immunology: Findings in inflammation immunology reported from Genzyme Corporationhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033258&HITNO=0&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033258&THISHREF=http://c.moreover.com/click/here.pl%3fz2535088585%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033258&HITNO=0&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033258&THISHREF=http://c.moreover.com/click/here.pl%3fz2535088585%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewsRX: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study;http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034853&HITNO=1&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034853&THISHREF=http://c.moreover.com/click/here.pl%3fz2536014104%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034853&HITNO=1&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034853&THISHREF=http://c.moreover.com/click/here.pl%3fz2536014104%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comHealthcare Sales & Marketing Network: Anthera reports FDA SPA for Phase III Varespladib A-002 studyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033451&HITNO=2&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033451&THISHREF=http://c.moreover.com/click/here.pl%3fz2535208988%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033451&HITNO=2&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033451&THISHREF=http://c.moreover.com/click/here.pl%3fz2535208988%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Enzyme Research: Research conducted at Pfizer Inc. has provided new information about enzyme researchhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033257&HITNO=3&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033257&THISHREF=http://c.moreover.com/click/here.pl%3fz2535088530%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033257&HITNO=3&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033257&THISHREF=http://c.moreover.com/click/here.pl%3fz2535088530%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewsRX: Inflammation collaborationhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032821&HITNO=4&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032821&THISHREF=http://c.moreover.com/click/here.pl%3fz2534826617%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032821&HITNO=4&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032821&THISHREF=http://c.moreover.com/click/here.pl%3fz2534826617%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comDrug Discovery News: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study;http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030796&HITNO=5&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030796&THISHREF=http://c.moreover.com/click/here.pl%3fz2533825184%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030796&HITNO=5&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030796&THISHREF=http://c.moreover.com/click/here.pl%3fz2533825184%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directorshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030113&HITNO=6&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030113&THISHREF=http://c.moreover.com/click/here.pl%3fz2533449130%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030113&HITNO=6&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030113&THISHREF=http://c.moreover.com/click/here.pl%3fz2533449130%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSmartBrief: High Plasma Phospholipase A2 Activity, Inflammation Markers, and LDL Alterations in Obesity With or Without Type 2 Diabeteshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030055&HITNO=7&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030055&THISHREF=http://c.moreover.com/click/here.pl%3fz2533409277%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030055&HITNO=7&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030055&THISHREF=http://c.moreover.com/click/here.pl%3fz2533409277%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMDLinx: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study;http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029889&HITNO=8&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029889&THISHREF=http://c.moreover.com/click/here.pl%3fz2533323563%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029889&HITNO=8&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029889&THISHREF=http://c.moreover.com/click/here.pl%3fz2533323563%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directorshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029441&HITNO=9&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029441&THISHREF=http://c.moreover.com/click/here.pl%3fz2533143447%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029441&HITNO=9&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029441&THISHREF=http://c.moreover.com/click/here.pl%3fz2533143447%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPhoenix Business Journal: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directorshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029365&HITNO=10&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029365&THISHREF=http://c.moreover.com/click/here.pl%3fz2533111508%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029365&HITNO=10&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029365&THISHREF=http://c.moreover.com/click/here.pl%3fz2533111508%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comAustin Business Journal: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directorshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029340&HITNO=11&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029340&THISHREF=http://c.moreover.com/click/here.pl%3fz2533094589%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029340&HITNO=11&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029340&THISHREF=http://c.moreover.com/click/here.pl%3fz2533094589%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSan Francisco Business Times: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directorshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029325&HITNO=12&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029325&THISHREF=http://c.moreover.com/click/here.pl%3fz2533090135%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029325&HITNO=12&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029325&THISHREF=http://c.moreover.com/click/here.pl%3fz2533090135%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comDenver Business Journal: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directorshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029321&HITNO=13&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029321&THISHREF=http://c.moreover.com/click/here.pl%3fz2533088559%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029321&HITNO=13&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029321&THISHREF=http://c.moreover.com/click/here.pl%3fz2533088559%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBoston Business Journal: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directorshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029314&HITNO=14&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029314&THISHREF=http://c.moreover.com/click/here.pl%3fz2533082285%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029314&HITNO=14&MSIZE=199&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Inflammation&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029314&THISHREF=http://c.moreover.com/click/here.pl%3fz2533082285%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTriad Business Journal: